This reference hub prioritizes regulatory and authoritative sources.
Regulatory Sources
U.S. Food and Drug Administration — LENVIMA prescribing information
The FDA labeling provides approved U.S. indications, dosage, warnings, adverse reactions, pharmacology and other prescribing information.
DailyMed — LENVIMA
DailyMed provides the current structured U.S. labeling record, including dosing, strengths and warnings.
European Medicines Agency — Lenvima EPAR
The EMA EPAR provides European authorization information, therapeutic indications and product information.
European Medicines Agency — Kisplyx
Kisplyx contains lenvatinib and is used in specified European renal-cell-carcinoma indications.
Manufacturer Sources
Eisai describes lenvatinib as an internally discovered and developed multi-receptor tyrosine kinase inhibitor.
Clinical Evidence
The EMA summarizes pivotal evidence in differentiated thyroid carcinoma and hepatocellular carcinoma.